Urinary DNA Methylation Biomarkers for Prediction of Prostate Cancer Upgrading and Upstaging

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2019 Aug 7

PMID 31383039

Citations 16

Authors

Arnas Bakavicius

Kristina Daniunaite

Kristina Zukauskaite

Marija Barisiene

Sonata Jarmalaite

Feliksas Jankevicius

Affiliations

Soon will be listed here.

Abstract

Background: Significant numbers of prostate cancer (PCa) patients experience tumour upstaging and upgrading in surgical specimens that cause serious problems in timely and proper selection of the treatment strategy. This study was aimed at the evaluation of a set of established epigenetic biomarkers as a noninvasive tool for more accurate PCa categorization before radical prostatectomy (RP).

Methods: Quantitative methylation-specific PCR was applied for the methylation analysis of RARB, RASSF1, and GSTP1 in 514 preoperatively collected voided or catheterized urine samples from the single-centre cohort of 1056 treatment-naïve PCa patients who underwent RP. The rates of biopsy upgrading and upstaging were analysed in the whole cohort.

Results: Pathological examination of RP specimens revealed Gleason score upgrading in 27.2% and upstaging in 20.3% of the patients with a total misclassification rate of 39.0%. DNA methylation changes in at least one gene were detected in more than 80% of urine samples. Combination of the PSA test with the three-gene methylation analysis in urine was a significant predictor of pathological upstaging and upgrading (P < 0.050), however, with limited increase in overall accuracy. The PSA test or each gene alone was not informative enough.

Conclusions: The urinary DNA methylation assay in combination with serum PSA may predict tumour stage or grade migration post-RP aiding in improved individual risk assessment and appropriate treatment selection. Clinical utility of these biomarkers should be proven in larger multi-centre studies.

Citing Articles

Prostate cancer epigenetics - from pathophysiology to clinical application.

Constancio V, Lobo J, Sequeira J, Henrique R, Jeronimo C Nat Rev Urol. 2025; .

PMID: 39820138 DOI: 10.1038/s41585-024-00991-8.

Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.

Saleh Z, Moccia M, Ladd Z, Joneja U, Li Y, Spitz F Int J Mol Sci. 2024; 25(2).

PMID: 38279330 PMC: 10816436. DOI: 10.3390/ijms25021331.

Gene methylation status in focus of advanced prostate cancer diagnostics and improved individual outcomes.

Zhang W, Zeng S, Gong L, Zhang D, Hu X Transl Androl Urol. 2024; 12(12):1813-1826.

PMID: 38196695 PMC: 10772650. DOI: 10.21037/tau-23-405.

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers.

Rafikova G, Gilyazova I, Enikeeva K, Pavlov V, Kzhyshkowska J Int J Mol Sci. 2023; 24(16).

PMID: 37628978 PMC: 10454494. DOI: 10.3390/ijms241612797.

The prognostic value of F-PSMA-1007 PET/CT in predicting pathological upgrading of newly diagnosed prostate cancer from systematic biopsy to radical prostatectomy.

Zheng A, Wang Z, Luo L, Chang R, Gao J, Wang B Front Oncol. 2023; 13:1169189.

PMID: 37234988 PMC: 10206242. DOI: 10.3389/fonc.2023.1169189.

References

Auprich M, Bjartell A, Chun F, De La Taille A, Freedland S, Haese A . Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011; 60(5):1045-54. DOI: 10.1016/j.eururo.2011.08.003. View

Partin A, Van Neste L, Klein E, Marks L, Gee J, Troyer D . Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014; 192(4):1081-7. PMC: 4337855. DOI: 10.1016/j.juro.2014.04.013. View

Le Nobin J, Orczyk C, Deng F, Melamed J, Rusinek H, Taneja S . Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software. BJU Int. 2014; 114(6b):E105-E112. PMC: 4714042. DOI: 10.1111/bju.12750. View

Stuopelyte K, Daniunaite K, Bakavicius A, Lazutka J, Jankevicius F, Jarmalaite S . The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer. 2016; 115(6):707-15. PMC: 5023772. DOI: 10.1038/bjc.2016.233. View

Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka J . Prognostic value of RASSF1 promoter methylation in prostate cancer. J Urol. 2014; 192(6):1849-55. DOI: 10.1016/j.juro.2014.06.075. View

Park J . Promoter hypermethylation as a biomarker in prostate adenocarcinoma. Methods Mol Biol. 2014; 1238:607-25. DOI: 10.1007/978-1-4939-1804-1_32. View

Calio B, Sidana A, Sugano D, Gaur S, Maruf M, Jain A . Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?. J Urol. 2017; 199(4):976-982. PMC: 7983157. DOI: 10.1016/j.juro.2017.10.048. View

Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V . Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. J Urol. 2016; 197(2):335-341. DOI: 10.1016/j.juro.2016.08.081. View

Mohler J, Antonarakis E, Armstrong A, DAmico A, Davis B, Dorff T . Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(5):479-505. DOI: 10.6004/jnccn.2019.0023. View

10.

Epstein J, Allsbrook Jr W, Amin M, Egevad L . The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29(9):1228-42. DOI: 10.1097/01.pas.0000173646.99337.b1. View

11.

Bratan F, Niaf E, Melodelima C, Chesnais A, Souchon R, Mege-Lechevallier F . Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol. 2013; 23(7):2019-29. DOI: 10.1007/s00330-013-2795-0. View

12.

Sehdev A, Pan C, Epstein J . Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Hum Pathol. 2001; 32(5):494-9. DOI: 10.1053/hupa.2001.24322. View

13.

Brassetti A, Lombardo R, Emiliozzi P, Cardi A, Antonio D, Antonio I . Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket. Urology. 2017; 111:129-135. DOI: 10.1016/j.urology.2017.07.071. View

14.

de la Calle C, Patil D, Wei J, Scherr D, Sokoll L, Chan D . Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. J Urol. 2015; 194(1):65-72. PMC: 4696043. DOI: 10.1016/j.juro.2015.01.091. View

15.

Moreira-Barbosa C, Barros-Silva D, Costa-Pinheiro P, Torres-Ferreira J, Constancio V, Freitas R . Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. Clin Epigenetics. 2018; 10(1):132. PMC: 6206889. DOI: 10.1186/s13148-018-0564-2. View

16.

Park J, Yoo S, Cho M, Cho M, Jeong C, Ku J . The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy. Biomed Res Int. 2018; 2018:4510149. PMC: 5952586. DOI: 10.1155/2018/4510149. View

17.

Muralidhar V, Dinh K, Mahal B, Ziehr D, Chen Y, Viswanathan V . Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015; 33(7):330.e19-25. DOI: 10.1016/j.urolonc.2015.03.010. View

18.

Capitanio U, Karakiewicz P, Valiquette L, Perrotte P, Jeldres C, Briganti A . Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology. 2009; 73(5):1087-91. DOI: 10.1016/j.urology.2008.10.048. View

19.

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View

20.

Caster J, Falchook A, Hendrix L, Chen R . Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients. Int J Radiat Oncol Biol Phys. 2015; 92(2):244-51. DOI: 10.1016/j.ijrobp.2015.01.051. View